Centre for Drug Design and Discovery-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Centre for Drug Design and Discovery - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014182
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution provides services such as silico molecule design, modelling and screening, medicinal chemistry, intellectual property rights support, business development, and others. It partners with various research institutions and companies to offer drugs for various disorders such as epilepsy, cancer, acquired immunodeficiency syndrome (AIDS), hepatitis C virus infections, arthritis, asthma, dengue virus infections, and Alzheimer’s disease. CD3 concentrates on various types of projects such as screening projects, rational design projects, and hit-to-lead projects. It also offers drug discovery and development services for the treatment of all kinds of diseases. CD3 is headquartered in Heverlee, Belgium.

Centre for Drug Design and Discovery – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Centre for Drug Design and Discover Enters into Co-Development Agreement with University of Turku 10
Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 11
Lead Discovery Center, Centre for Drug Design and Discovery and Axxam Form Joint Venture 12
Licensing Agreements 13
AstraZeneca Enters Into Licensing Agreement with VIB and CD3 13
Centre for Drug Design and Discovery – Key Competitors 14
Centre for Drug Design and Discovery – Key Employees 15
Centre for Drug Design and Discovery – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Joint Venture 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Key Facts 2
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Centre for Drug Design and Discovery, Deals By Therapy Area, 2011 to YTD 2017 8
Centre for Drug Design and Discovery, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Centre for Drug Design and Discover Enters into Co-Development Agreement with University of Turku 10
Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 11
Lead Discovery Center, Centre for Drug Design and Discovery and Axxam Form Joint Venture 12
AstraZeneca Enters Into Licensing Agreement with VIB and CD3 13
Centre for Drug Design and Discovery, Key Competitors 14
Centre for Drug Design and Discovery, Key Employees 15
Centre for Drug Design and Discovery, Joint Venture 16

★海外企業調査レポート[Centre for Drug Design and Discovery-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Simon Property Group, Inc.:企業のM&A・事業提携・投資動向
    Simon Property Group, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Simon Property Group, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Stryker Corp (SYK):企業の財務・戦略的SWOT分析
    Stryker Corp (SYK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Mersen SA (MRN):電力:M&Aディール及び事業提携情報
    Summary Mersen SA (Mersen), formerly known as Groupe Carbone Lorraine SA, is a manufacturer of electrical power and advanced materials. It design and innovate solutions to address its clients need in specific markets. The company’s product portfolio comprises solutions such as carbon products, graph …
  • FibroStatin SL:製薬・医療:M&Aディール及び事業提携情報
    Summary FibroStatin SL (FibroStatin) is a drug development company that focuses on the development of treatment candidates for drug resistant lung cancer and idiopathic pulmonary fibrosis. The company’s pipeline products include T12/FST12 for NSCLC, GPBP-Mab/FSM26 for idiopathic pulmonary fibrosis a …
  • L’Oreal SA:企業の戦略・SWOT・財務情報
    L'Oreal SA - Strategy, SWOT and Corporate Finance Report Summary L'Oreal SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Maharashtra State Power Generation Co Ltd-エネルギー分野:企業M&A・提携分析
    Summary Maharashtra State Power Generation Co., Ltd. (Mahagenco) is a state government-owned electricity company. The company generates and supplies electricity across the state of Maharashtra, India. Mahagenco owns and operates generation facilities, and uses diverse fuel sources such as thermal, g …
  • Credit Saison Co., Ltd.:企業の戦略・SWOT・財務情報
    Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Sinopec Shanghai Petrochemical Company Limited:企業の戦略・SWOT・財務情報
    Sinopec Shanghai Petrochemical Company Limited - Strategy, SWOT and Corporate Finance Report Summary Sinopec Shanghai Petrochemical Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Orezone Gold Corporation:企業の戦略・SWOT・財務情報
    Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • IntelGenx Corp:企業のM&A・事業提携・投資動向
    IntelGenx Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IntelGenx Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Genenta Science srl:製薬・医療:M&Aディール及び事業提携情報
    Summary Genenta Science srl (Geneta Science) is a biotechnology company that develops gene therapies based on transcriptional and mirRNA-mediated controls. The company develops gene transfer strategy into autologous hematopoietic stem and progenitor cells in order to target interferon-a expression t …
  • Daito Trust Construction Co., Ltd.:企業の戦略・SWOT・財務分析
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • National Research Council of Canada:企業のM&A・事業提携・投資動向
    National Research Council of Canada - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's National Research Council of Canada Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Memorial Health System:企業の戦略的SWOT分析
    Memorial Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Jumeirah Group:企業の戦略・SWOT・財務分析
    Jumeirah Group - Strategy, SWOT and Corporate Finance Report Summary Jumeirah Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Austrian Post:企業の戦略・SWOT・財務情報
    Austrian Post - Strategy, SWOT and Corporate Finance Report Summary Austrian Post - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • China Haisheng Juice Holdings Co Ltd:企業の戦略・SWOT・財務分析
    China Haisheng Juice Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Haisheng Juice Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Immatics Biotechnologies GmbH:企業の戦略的SWOT分析
    Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Andhra Bank (ANDHRABANK):企業の財務・戦略的SWOT分析
    Andhra Bank (ANDHRABANK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ICON Plc (ICLR)-製薬・医療分野:企業M&A・提携分析
    Summary ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides a range of specialized services that span the entire lifecycle of product development. The company …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆